Social Media Ideas for Citius Oncology

Citius Oncology of Cranford says commercial response to cancer treatment is strong

Citius Oncology Inc., an oncology‑focused biopharmaceutical company and majority‑owned subsidiary of Citius Pharmaceuticals Inc., provided an update Aug. 5 on the expanding base of...

Oncology

Oncology Anonymous (not verified) Tue, 08/11/2026 - 00:32 field_thread_url https://cafepharma.com/boards/threads/oncology.709375/ board...

<![CDATA[BeOne Medicines Enters Collaboration with Revolution Medicines for Oncology Therapies ]]>

SA Asks: What are the most promising oncology companies right now?

Big Pharma-backed AdvanCell, flush with $315M series D, ready to put radiotherapy pedal to the metal

Less than a month after locking down a lease for a new U.S. headquarters, radiotherapy outfit AdvanCell is poised to push its lead prostate cancer candidate into phase 3 developmen...

<![CDATA[M&A Roundup: Pathos AI Enter’s Licensing Agreements with AstraZeneca & Alphamab Oncology, Curium Ent...

Lupin Spins Out Two Oncology Programs to Kaveri Therapeutics to Advance its Oncology Strategy

Aims to Raise Capital to Fund Global Clinical Studies for LNP7457 (PRMT5) & LNP8701 (SOS1)

NexTel Medical Corp. Advances Veterinary Oncology Strategy with Rollout of Early-Stage Cancer Screening for Companion An...

Company targets a growing $1.2B+ North American pet oncology market leveraging proprietary exosome-based diagnostic technologies.

Cureety acquires Reimagine Care for AI-driven precision oncology

The two companies now support more than 250 cancer centers—covering more than 100,000 patients—across five countries, executives say.

Arcus: 'Buy' On Casdatifan Late-Stage CcRCC Advancement And 1st-Line Expansions

Exsure is working on a way to make chemotherapy less toxic, backed by peer-reviewed research

The Bhubaneswar biotech has built a patented drug-delivery platform aimed at cancer cells. It is in preclinical testing and raised Rs 3 crore, led by Unicorn India Ventures.

Cullinan tees up J&J fight—and $100M payday—as Taiho-partnered drug hits phase 3 cancer goal

Taiho Pharmaceutical and Cullinan Therapeutics have celebrated a second phase 3 victory for their small-molecule EGFR inhibitor, teeing up the partners to challenge Johnson & J...

New Taiho, Cullinan data heats up lung cancer drug battle

The findings position their drug, zipalertinib, as a threat to multiple approved medicines — while setting a bar for others in testing.

Merck and Sarah Cannon team up to boost oncology trial efficiency

Oncology R&D organization Sarah Cannon Research Institute (SCRI) announced a collaboration with Merck & Co. to increase patient access to oncology trials at community-based...

Merck and Sarah Cannon team up to boost oncology trial efficiency

Oncology R&D organization Sarah Cannon Research Institute (SCRI) announced a collaboration with Merck & Co. to increase patient access to oncology trials at community-based...

Citius Oncology appoints independent director Peri to board of directors

Citius Oncology, Inc., an oncology-focused biopharmaceutical company and majority-owned subsidiary of Citius Pharmaceuticals, Inc., announced that its board of directors voted to a...

OncoLens' AI-Powered Analytics Platform Helps Large Academic Cancer Center in Florida Cut Referral Delays and Surface Ca...

Case study finds nearly 9 in 10 actionable cancer data points existed only in unstructured text invisible to standard EMR reporting; OncoLens Analytics helped the center lift on-ti...

Pathos Picks Up Two Cancer Drugs Poised for Clinical Development With AI Agents

Pathos AI struck a deal for rights to a bispecific antibody drug conjugate from Alphamab that could become first in a new class of cancer drugs. Separately, the startup began a par...

How East Ocyon Bio is building an off-the-shelf cancer cell therapy in Gurugram

The Gurugram-based company is developing allogeneic CAR-NK cell therapies made from healthy donor cells, backed by a $4.2 million seed round and a government grant covering both re...

Tempus to buy cancer test-maker Personalis for $1.5B

Tempus AI’s planned acquisition follows recent interest in blood-based cancer tests across the medtech industry.

Tempus to acquire cancer test maker Personalis for $1.5B

Tempus AI’s planned acquisition follows recent interest in blood-based cancer tests across the medtech industry.

Natera teams with Angiex on cancer drug trial monitoring

Natera inked a collaboration deal with biotech Angiex to assess the use of its Signatera blood test, which looks for small traces of cancer DNA in patients who have been diagnosed...

Priority Health Launches 2 Cancer Support Solutions with Color Health, Grail

Priority Health partnered with Color Health and Grail to offer self-funded employers virtual cancer navigation, support and multi-cancer early detection beginning in 2027. The post...

Genentech doubles down on ADC-resistant cancers with $1B DualityBio pact

Roche’s Genentech is paying DualityBio $45 million upfront for rights to antibody-drug conjugates (ADCs) designed for the growing pool of patients who progress after treatment with...